Mineralys Therapeutics (MLYS) Q3 2026 earnings review
Mineralys hires its sales team, so quarterly losses widen
Mineralys Therapeutics, a drug developer with no commercial revenue yet, is spending heavily to build a sales team before US regulators rule on its blood pressure pill. Chief executive Jon Congleton said the focus is on finishing launch preparations ahead of the December 22 decision date, and the company now has its sales force in place. That hiring nearly quadrupled overhead costs from a year ago to $37 million, pushing the quarterly net loss to $57 million while cash dipped to $625 million.
| Operating expenses | $60.1M +31% from last quarter, excluding one-offs |
|---|---|
| General and administrative expenses | $37.4M nearly quadrupled from $9.7M a year ago |
| Cash, cash equivalents and investments | $624.7M -$36.7M from last quarter |
| Cash funding outlook | Unchanged funds launch operations into 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because everything still hinges on the December regulatory decision, though the launch cost build is now visible in the financial statements. New kidney disease data strengthened the medical case for the pill, lorundrostat. One caution: keeping the cash funding outlook at into 2028 implies by our math that quarterly cash drain will nearly triple toward $104 million as the launch begins.
The question now is whether a small company launching on its own can win insurance coverage and doctor prescriptions fast enough to cover a much heavier cost base. Either the kidney and blood pressure data carve out a profitable niche alongside AstraZeneca's rival drug, or slow early sales against high launch expenses force another stock sale. The December 22 regulatory decision and initial pricing disclosures in early 2027 will tell.
🐂 Bull Case
Sales Team Is Hired Ahead of December Decision
Mineralys is preparing to sell lorundrostat, its experimental pill for high blood pressure, on its own. “As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval,” chief executive Jon Congleton said. The PDUFA date is the deadline for US regulators to decide on approving the drug.
The biotechnology company “now has an expanded medical affairs team and sales force in place” and is finishing a patient support programme. That hiring pushed general and administrative expenses — overhead, legal and commercial preparation costs — up 287% from a year ago to $37.4 million. Professional fees rose by $15.4 million and staff costs grew by $11.4 million, lifting total operating expenses 30.5% from last quarter, excluding one-offs, by our math.
What to watch: the exact size of the sales force and initial payer coverage on the fourth-quarter call. Having representatives hired before December means the drug developer can promote lorundrostat to doctors immediately upon approval.
Blood Pressure Drug Works Across Kidney Disease Stages
Mineralys wants doctors to see lorundrostat as a treatment for patients whose blood pressure stays high despite taking multiple pills, especially those with chronic kidney disease (CKD). New analyses from its main Launch-HTN trial presented at medical meetings this quarter backed up that pitch, while a separate sleep apnea study showed no cases of dangerously high blood potassium.
- Blood pressure goal: 46% of patients on the 50 mg dose reached the guideline target below 130 mmHg at Week 12
- Overall drop: more than two-thirds of patients saw systolic blood pressure fall by at least 10 mmHg
- Kidney protection: reduced albuminuria, a protein in urine that signals kidney damage, by 52% compared with placebo across Stages 1 to 3 CKD
These results matter because kidney patients often cannot tolerate older aldosterone-blocking drugs due to potassium risks. Showing consistent blood pressure drops and lower kidney protein across disease stages gives the sales team data to distinguish lorundrostat from rivals.
What to watch: the final FDA-approved prescribing label on or before December 22, 2026. A label that allows use across kidney disease stages without strict potassium warnings would help the drug compete for high-risk patients.
🐻 Bear Case
FDA Decision Carries a $350 Million Balance-Sheet Swing
Last quarter Mineralys built its war chest by raising $150 million in stock, drawing $100 million from a loan facility of up to $500 million, and paying $200 million upfront to Tanabe to buy out future royalties. That setup leaves the company with $624.7 million in cash and investments and $98.3 million in debt, but ties its financial flexibility to the December 22 regulatory decision.
Because the company paid Tanabe before winning approval, a rejection or delay by regulators would strand that $200 million upfront payment. It would also block access to the next $150 million loan tranche, which requires regulatory approval before April 30, 2027. Worse, if the drug is not approved by September 30, 2027, the existing $100 million loan begins requiring quarterly repayments of about $25 million.
What to watch: the FDA decision on lorundrostat by December 22, 2026. An approval unlocks $150 million in committed debt funding and validates the royalty buyout, while a rejection triggers a debt repayment clock nine months later.
Launch Costs Will Nearly Triple the Cash Drain
Mineralys said its $624.7 million in cash, cash equivalents and investments “will be sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028”. In the third quarter, the company's cash and investments balance fell by $36.7 million from last quarter, by our math, as clinical trial savings partially offset higher commercial hiring.
While a $624.7 million balance looks large against a $36.7 million quarterly drop, the company's own timeline points to a sharp jump in spending. Stretching that cash across the six quarters from October 2026 into early 2028 implies an average cash drain of about $104 million a quarter by our math, nearly triple this quarter's pace. The drug maker also owes Tanabe up to $255 million in commercial milestones, starting with an undisclosed payment upon the first commercial sale.
What to watch: first-quarter 2027 operating expenses and the disclosure of the first-sale milestone payment to Tanabe. If early prescription sales start slowly against a $100 million quarterly spending rate, the cushion will shrink quickly.
Risks this quarter didn't answer
Four standing commercial and financial risks received no new numbers or updates in the third-quarter release.
- Entering second behind AstraZeneca's baxdrostat: no update on how Mineralys will counter a larger rival that sets doctor habits early; launch prescription tracking in 2027 will test this.
- Pricing and insurance rebates: the release notes ongoing payer talks but gives no list price or rebate tier; the launch pricing announcement after December 22 will settle it.
- Going it alone without a partner: partnering went unmentioned as the company hired its own sales force; any commercial co-promotion deal around approval would change this.
- Loan revenue requirement: the minimum product revenue level required by lenders starting in 2028 remains undisclosed; the quarterly filing or 2027 sales updates will show how tight the rule is.
👓 Other Themes
Sleep Apnea Trial Misses Breathing Goal
Final results from the Phase 2 Explore-OSA trial in overweight adults with sleep apnea and high blood pressure confirmed that lorundrostat does not fix nighttime breathing pauses. The pill cut morning systolic blood pressure by 11.1 mmHg at Week 4 versus 1.0 mmHg on placebo, but showed no measurable change on the apnea-hypopnea index, which counts breathing stops per hour. Sleep apnea remains a blood pressure marketing angle rather than a separate disease target.
💲 Other KPIs
Research and development spending — the cost of running clinical trials and manufacturing drug supply — fell 27.9% from $31.5 million a year ago because the main lorundrostat blood pressure trials wrapped up in the second quarter of 2025. Excluding last quarter's $200 million royalty buyout charge, research spending ticked up 6.0% from $21.4 million in the second quarter, by our math.
The share count rose 26.1% from 70.6 million a year ago and 5.0% from 84.7 million last quarter. The increase reflects the full-quarter impact of the 5.7 million shares sold in the June 2026 public stock offering and earlier stock sales used to fund the launch and royalty buyout.
Net other income — interest earned on cash minus interest paid on debt — dropped 34.3% from $4.2 million a year ago and 44.5% from $5.0 million last quarter. Higher interest income on the cash pile (+$1.8 million from a year ago) was outweighed by $3.2 million in interest expense on the $100 million loan drawn in June.
🔮 Guidance
Unchanged. Mineralys still expects its $624.7 million in cash, cash equivalents and investments to fund planned operations and the lorundrostat launch into 2028. By our math, spending that balance over the six quarters from October 2026 through early 2028 implies an average cash outflow of about $104 million per quarter, up from a $36.7 million cash drop in the third quarter.
❓ Key Questions
How many sales representatives did Mineralys hire for launch?
The company confirmed its sales force is now in place and general and administrative costs jumped to $37.4 million, but it did not disclose how many representatives will cover the roughly 50,000 target doctors.
What is the first-sale payment owed to Tanabe?
Mineralys owes up to $255 million in commercial milestones to Tanabe starting upon the first commercial sale, and knowing the exact initial payout is necessary to judge first-quarter 2027 cash needs.
Does the 2028 cash plan include the $150 million loan draw?
The outlook says current cash of $624.7 million funds the business into 2028, implying over $100 million in quarterly burn, so investors need to know what quarterly operating expense run-rate the plan assumes.
What is the 2028 minimum revenue rule on the loan?
The senior secured loan includes a minimum product revenue requirement starting in 2028 secured by the company's assets, but the threshold needed to avoid a violation remains undisclosed.